Evidence map›Paper›PMID 41372494›Full record

ArticleJournal of hematopathology2025

Acute promyelocytic leukemia with a rare TBL1XR1::RARA fusion and distinctive morphologic and phenotypic attributes.

Peter Halloran, Mark Montgomery, Hamza Tariq

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peter HalloranCreighton University School of Medicine, Omaha, NE, 68178, USA.
Mark MontgomeryDepartment of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E. Huron St. 7-213F, Chicago, IL, 60611, USA.
Hamza TariqDepartment of Pathology, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, 251 E. Huron St. 7-213F, Chicago, IL, 60611, USA. hamza.tariq@northwestern.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute promyelocytic leukemias (APL) with variant translocations involving the RARA gene at 17q21.2 with non-PML partners constitute a rare and diverse subset of APLs, accounting for approximately 5% of total cases. Variant APLs present considerable diagnostic challenges, as standard testing methodologies targeting the PML::RARA fusion protein are unrevealing, leading to a lack of diagnosis. CASE PRESENTATION: We present the case of a 54-year-old patient with APL harboring a TBL1XR1::RARA fusion, an exceptionally rare APL variant that showed distinctive morphologic, phenotypic, and clinical attributes. Unlike conventional APL, the neoplastic promyelocytes lacked pathognomonic Auer rods and bilobed nuclei and were accompanied by marked granulocytic dysplasia and significant monocytosis. Phenotypically, the blasts were negative for CD117 and showed an associated expanded monocyte population with aberrant CD56 and CD23 expression, features highly uncharacteristic of classic APL. Cytogenetic analysis and targeted PCR yielded negative results for PML::RARA fusion; however, the break-apart probe analysis tested positive for a RARA rearrangement, ultimately facilitating an accurate diagnosis. The patient did not respond to all-trans retinoic acid (ATRA) and succumbed to the disease 24 days after the initial presentation.

conclusionsThis case brings to light the diagnostic challenges posed by variant APLs that may demonstrate divergent morphologic and phenotypic features and carry translocations that render the routine PML::RARA fusion-based methodologies futile. Accurate diagnosis requires a high index of suspicion and a comprehensive multifaceted diagnostic strategy that encompasses morphologic assessment, immunophenotypic analysis, RARA break-apart probe analysis supplementing traditional fusion probe techniques, conventional karyotyping, and advanced molecular fusion testing.

Indexed as

Leukemia, Promyelocytic, AcuteOncogene Proteins, FusionReceptors, Cytoplasmic and NuclearRepressor ProteinsRetinoic Acid Receptor alphaHumansMaleMiddle AgedPhenotypeTranslocation, GeneticOncogene Proteins, FusionRARA protein, humanReceptors, Cytoplasmic and NuclearRepressor ProteinsRetinoic Acid Receptor alphaTBL1XR1 protein, humanAcute promyelocytic leukemia (APL)All-trans retinoic acid (ATRA)TBL1XR1Variant

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.